These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22940072)

  • 41. Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.
    Chen GL; Carpenter PA; Broady R; Gregory TK; Johnston LJ; Storer BE; Beumer JH; Qiu J; Cerda K; Le R; Otani JM; Liu H; Ross MA; Arai S; Flowers MED; McCarthy PL; Miklos DB
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):373-380. PubMed ID: 29051021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Defining and managing imatinib resistance.
    Mauro MJ
    Hematology Am Soc Hematol Educ Program; 2006; ():219-25. PubMed ID: 17124064
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.
    Chhina MK; Nargues W; Grant GM; Nathan SD
    Future Cardiol; 2010 Jan; 6(1):19-35. PubMed ID: 20014985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis.
    Akashi N; Matsumoto I; Tanaka Y; Inoue A; Yamamoto K; Umeda N; Tanaka Y; Hayashi T; Goto D; Ito S; Sekiguchi K; Sumida T
    Mod Rheumatol; 2011 Jun; 21(3):267-75. PubMed ID: 21188449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.
    Pai CS; Khuat LT; Chen M; Murphy WJ; Abedi M
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):30-37. PubMed ID: 27815049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
    Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
    Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation.
    Zhang Y; McCormick LL; Desai SR; Wu C; Gilliam AC
    J Immunol; 2002 Mar; 168(6):3088-98. PubMed ID: 11884483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abl family kinases regulate endothelial barrier function in vitro and in mice.
    Chislock EM; Pendergast AM
    PLoS One; 2013; 8(12):e85231. PubMed ID: 24367707
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imatinib for refractory chronic graft-versus-host disease with fibrotic features.
    Olivieri A; Locatelli F; Zecca M; Sanna A; Cimminiello M; Raimondi R; Gini G; Mordini N; Balduzzi A; Leoni P; Gabrielli A; Bacigalupo A
    Blood; 2009 Jul; 114(3):709-18. PubMed ID: 19403889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Imatinib attenuates skeletal muscle dystrophy in mdx mice.
    Huang P; Zhao XS; Fields M; Ransohoff RM; Zhou L
    FASEB J; 2009 Aug; 23(8):2539-48. PubMed ID: 19289603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Attenuation of murine sclerodermatous models by the selective S1P
    Kano M; Kobayashi T; Date M; Tennichi M; Hamaguchi Y; Strasser DS; Takehara K; Matsushita T
    Sci Rep; 2019 Jan; 9(1):658. PubMed ID: 30679645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts.
    Bujor AM; Asano Y; Haines P; Lafyatis R; Trojanowska M
    Arthritis Rheum; 2011 Jun; 63(6):1729-37. PubMed ID: 21321929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Imatinib].
    Urabe A
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.
    Gobin B; Moriceau G; Ory B; Charrier C; Brion R; Blanchard F; Redini F; Heymann D
    PLoS One; 2014; 9(3):e90795. PubMed ID: 24599309
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
    J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.
    Rosenberg A; Mathew P
    Expert Opin Investig Drugs; 2013 Jun; 22(6):787-94. PubMed ID: 23540855
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
    Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
    Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
    Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M
    Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy.
    Lazar J; Poonawalla T; Teng JM
    Pediatr Dermatol; 2011; 28(2):172-5. PubMed ID: 21504445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.